All Stories

  1. Early reported effects of the 2026 CMS Physician Fee Schedule on patient access to CAMPs in wound care: a national clinician and practice survey
  2. Rethinking regulatory tiers: Medicare real-world evidence shows CAMP outcomes are independent of FDA regulatory classification
  3. Real-world outcomes of a placenta-based tissue product versus standard of care for lower extremity diabetic ulcers: a Medicare cohort study
  4. Safeguarding access, fiscal responsibility and innovation: a comprehensive reimbursement framework for CAMPs to preserve the Medicare Trust Fund
  5. The hidden costs of limiting access: clinical and economic risks of Medicare’s future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination
  6. Innovative treatment of diabetic ulcers: combining chemical debridement and xenograft applications: a case study
  7. A review of the proposed draft CAMPs LCDs compared to evidence-based medicine: a letter to the MACs for consideration
  8. Dehydrated human amnion/chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis
  9. Treatment patterns and outcomes of Medicare enrolees who developed venous leg ulcers
  10. Dehydrated human amnion chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis
  11. Current practices using cellular, acelluar and matrix-like products (CAMPs)
  12. Treatment patterns and outcomes of Medicare enrolees who developed venous leg ulcers
  13. Dehydrated human amnion/chorion membrane use in emergent craniectomies shows minimal dural adhesions
  14. Deep palm burn treated with enzymatic debridement followed by autologous skin cell suspension
  15. Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs)
  16. Pyoderma gangrenosum and dehydrated human amnion/chorion membrane: a potential tool for an orphan disease
  17. Outcomes for Medicare debridement intervals receiving dehydrated human amnion/chorion membrane
  18. The influence of adequate debridement and placental-derived allografts on diabetic foot ulcers
  19. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment
  20. Expandable Dehydrated Human Umbilical Cord Allograft for the Management of Nonhealing Lower Extremity Wounds in Patients With Diabetes: A Case Series
  21. Limb Salvage Using Human Placental Allografts: Adding to the Reconstructive Ladder Paradigm
  22. Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015–2018)
  23. Unique closure of an open fracture complicated with a hard-to-heal lower extremity wound
  24. Complex Limb Salvage with Placental-Based Allografts: A Pilot Study
  25. TIMERS: expanding wound care beyond the focus of the wound
  26. The use of placental derived membrane allograft on infected ruptured AV fistula revision and closure
  27. Variations in study outcomes relative to intention‐to‐treat and per‐protocol data analysis techniques in the evaluation of efficacy for treatment of venous leg ulcers with dehydrated human amnion/chorion membrane allograft
  28. Implementing TIMERS: the race against hard-to-heal wounds
  29. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers
  30. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics